Cardiovascular safety warnings for the gout drug febuxostat should be reconsidered in light of new findings showing no increased risk of cardiovascular adverse events or mortality, researchers say. Professor Nicola Dalbeth, a rheumatologist at Auckland University is one of several co-authors of a new paper that calls for reassessment of the cardiovascular safety of febuxostat ...
Call for FAST re-think on febuxostat cardiovascular warnings
By Michael Woodhead
2 Feb 2021